• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Intern Med . Time Course of Coagulopathy Evaluated with Rotational Thromboelastometry in Patients with Severe Coronavirus disease 2019

tetano

Editor, Senior Moderator
Intern Med


. 2022 Dec 21.
doi: 10.2169/internalmedicine.0993-22. Online ahead of print.
Time Course of Coagulopathy Evaluated with Rotational Thromboelastometry in Patients with Severe Coronavirus disease 2019


Takeshi Yagi[SUP] 1 [/SUP], Motoki Fujita[SUP] 1 [/SUP], Kayoko Harada[SUP] 1 [/SUP], Masaru Shin[SUP] 1 [/SUP], Yusuke Esaki[SUP] 1 [/SUP], Ryo Ayata[SUP] 1 [/SUP], Yasutaka Koga[SUP] 1 [/SUP], Kotaro Kaneda[SUP] 1 [/SUP], Ryosuke Tsuruta[SUP] 1 [/SUP]



Affiliations

Abstract

Objectives Coronavirus disease 2019 (COVID-19) reportedly causes thromboembolic complications due to coagulopathy with hypercoagulability and a hypofibrinolytic state. We evaluated the time-course of coagulopathy in patients with severe COVID-19 from admission to discharge from our intensive-care unit (ICU). Methods We conducted a retrospective study of adults with severe COVID-19 admitted to our ICU between January 20, 2021, and March 31, 2022. We obtained clinical information, laboratory data, and rotational thromboelastometry (ROTEM) parameters at admission and discharge. Results Fifteen patients were included. Fibrinogen and D-dimer values did not change significantly but were above the normal ranges at admission and discharge. Regarding ROTEM parameters, the maximum clot firmness in fibrinogen function (FIBTEM), a marker of hypercoagulability, did not change significantly but was above the normal range at admission and discharge (median [interquartile range], admission vs. discharge: 31 [25-34] mm vs. 31 [27-32] mm, P = 0.589). The maximum lysis at 60 minutes in the extrinsic coagulation pathway (EXTEM) and intrinsic coagulation pathway (INTEM), as markers of the fibrinolytic function, were both significantly lower at discharge than at admission (median [interquartile range], admission vs. discharge: EXTEM, 3 [2-4] vs. 1 [0-2], P = 0.011; INTEM, 3 [1-6] vs. 1 [0-2], P = 0.008). Conclusion This study revealed a persistent hypercoagulable state at ICU discharge and a worse hypofibrinolytic state at discharge than at admission. These results may contribute to a better understanding of coagulopathies in the acute to subacute phases of severe COVID-19.

Keywords: COVID-19; coagulopathy; hypercoagulability; hypofibrinolysis; thromboelastometry.
 
Back
Top Bottom